Loading...
01/10 16:39
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed sentiment. While there are positive elements like strong cash position and potential revenue from PRGN-2012, there are concerns over increased net loss and supply chain risks. The Q&A highlights FDA interactions and market strategy, but management's evasiveness on key timelines adds uncertainty. Overall, the financial health and strategic outlook balance out the negatives, leading to a neutral sentiment prediction.
Net Loss $126.2 million (up from $95.9 million), attributed to increased operational costs and over $55 million in non-cash charges.
Net Loss per Share $0.47 per basic and diluted share (up from $0.39), reflecting the overall increase in net loss.
Cash Burn $76.8 million, indicating cash used in operations plus capital expenditures.
Funds Raised via Preferred Stock Issuance $79 million, which included warrants to purchase common stock, aimed at strengthening the balance sheet.
Cash, Cash Equivalents, and Investments $97.9 million at year-end, providing a financial runway expected to last well into 2026.
Proceeds from Sale of Intellectual Property Rights $8.5 million, contributing to the strengthening of the balance sheet.
PRGN-2012: Lead asset PRGN-2012 is on the verge of commercialization for RRP, with a BLA submission accepted by the FDA and a PDUFA date of August 27, 2025.
PRGN-2009: PRGN-2009 targets HPV-16 and HPV-18, showing a 30% objective response rate in relapsed-refractory patients, with ongoing Phase 2 trials.
UltraCAR-T: UltraCAR-T platform allows for overnight delivery of autologous CAR-T therapy, with promising data in AML and autoimmune settings.
Market Opportunity for PRGN-2012: Updated analytics suggest up to 27,000 adult patients in the US with RRP, indicating a greater unmet need than previously estimated.
Commercialization Strategy: Partnership with EVERSANA for US launch, focusing on training and deployment of dedicated field teams.
GMP Manufacturing: In-house GMP facility upgraded for PRGN-2012 drug substance manufacturing, ensuring control over production and quality.
Financial Position: Finished 2024 with $97.9 million in cash, supporting operations through anticipated PRGN-2012 launch and beyond.
Shift to Commercialization: Transitioning from R&D to commercialization with a focus on PRGN-2012 as the first medical treatment for RRP.
Regulatory Risks: The company is awaiting FDA approval for PRGN-2012, with a PDUFA date set for August 27, 2025. The success of commercialization is contingent on this approval.
Financial Risks: Precigen reported a net loss of $126.2 million for 2024, indicating financial strain. The company raised $79 million through preferred stock issuance, which carries an 8% dividend, adding to financial obligations.
Market Risks: The company faces competitive pressures in the market for RRP treatments, with the need to establish a strong market presence upon launch.
Supply Chain Challenges: While the company has built in-house GMP manufacturing capabilities, reliance on external vendors for fill/finish operations may pose risks to supply chain stability.
Economic Factors: The overall economic environment may impact funding and investment opportunities, affecting the company's ability to sustain operations and growth.
PRGN-2012 Commercialization: Precigen is on the verge of commercializing PRGN-2012, with a BLA submission accepted by the FDA and a PDUFA date set for August 27, 2025.
Manufacturing Strategy: Precigen has built an in-house GMP facility for adenovirus drug substance manufacturing and upgraded it to support the commercial launch of PRGN-2012.
Commercialization Team: Precigen has completed the build-out of its commercial leadership team and established a partnership with EVERSANA for the US launch.
Market Opportunity: Updated analytics suggest up to 27,000 adult patients in the US are living with RRP, indicating a greater unmet need for PRGN-2012.
PRGN-2009 and UltraCAR-T Programs: Updates on PRGN-2009 targeting HPV-related cancers and UltraCAR-T platform for AML and autoimmune settings were provided, highlighting ongoing clinical advancements.
Revenue Projections: Commercial revenues from PRGN-2012 are expected to begin in the second half of 2025, contingent on FDA approval.
Financial Position: Precigen finished 2024 with $97.9 million in cash, expected to support operations beyond the anticipated launch date and into 2026.
Net Loss: Precigen reported a net loss of $126.2 million for 2024, compared to $95.9 million in 2023.
Cash Burn: The cash burn for 2024 totaled $76.8 million, including operations and capital expenditures.
Funding and Financial Strategy: Precigen raised $79 million through preferred stock issuance and $8.5 million from monetizing non-core assets, strengthening its balance sheet.
Preferred Stock Dividend Rate: The preferred stock carries an 8% dividend, with the first two years to be paid in kind, and cash payments beginning in the third year, contingent upon declaration by the Board of Directors.
Preferred Stock Issuance: Precigen raised $79 million at the end of 2024 via a preferred stock issuance, which included warrants to purchase common stock.
Cash Position: The company finished the year with cash, cash equivalents, and investments of $97.9 million, which is expected to support operations well into 2026.
Revenue Projections: Anticipated revenue from the commercialization of PRGN-2012 is included in projections, contingent upon successful FDA approval.
The earnings call summary and Q&A reveal positive aspects: expansion plans, optimistic guidance on reaching cash breakeven, and strong market momentum for PAPZIMEOS. Despite some risks like cold chain logistics and regulatory compliance, the company’s financial health is stable with $123.6 million in cash and investments. The Q&A reassures on patient reimbursement and market adoption. The stock price is likely to react positively in the short-term, driven by optimistic guidance and market expansion strategies.
The earnings call reflects mixed signals: strong cash position and anticipated demand for PRGN-2012 suggest positive sentiment. However, increased net loss, operational risks, and competitive pressures temper optimism. The Q&A highlights management's cautious communication about FDA interactions and market capture, which adds uncertainty. Considering these factors, the stock price is expected to remain stable.
The earnings call presents a mixed sentiment. While there are positive elements like strong cash position and potential revenue from PRGN-2012, there are concerns over increased net loss and supply chain risks. The Q&A highlights FDA interactions and market strategy, but management's evasiveness on key timelines adds uncertainty. Overall, the financial health and strategic outlook balance out the negatives, leading to a neutral sentiment prediction.
The earnings call highlights significant financial concerns, including a large net loss and workforce reduction, which could affect operational capacity. The equity issuance and cash on hand provide limited runway. Positive aspects like the PRGN-2012 progress and global ambitions are overshadowed by vague management responses and market access challenges. The Q&A session reveals analyst concerns about FDA meetings and global strategy clarity. Overall, the negative financial outlook and uncertainties suggest a negative stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
